4-way competition in the Novel Oral Anticoagulant(NOAC) market
Competition is expected to be fiercer in the rapidly growing NOAC market.
As Daiichi Sankyo launched Lixiana with the insurance benefit on the 1st of February, the 3-way competition among Xarelto, Pradaxa and Eliquis has been re-fueled in the oral NOAC(Novel Oral Anticoagulant) market.
Accordin...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
